Neuraxis, Inc cash flow statement

In fiscal 2025, Neuraxis, Inc's operations generated −$6.4m of cash; it spent $31,150 on capital projects, leaving free cash flow of −$6.5m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Neuraxis, Inc: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−2,298	−6,694	−6,098	−6,433	−5,621
Depreciation and amortisation	37	41	38	60	73
Stock-based pay	27	0	227	597	487
Capital spending	1	31	28	31	0
Free cash flow	−2,299	−6,725	−6,126	−6,464	−5,621
Free cash flow after stock pay	−2,327	−6,725	−6,353	−7,061	−6,108
Shares issued	—	4,847	—	7,728	7,789

US$ thousands unless shown otherwise. Fiscal quarters.

Neuraxis, Inc: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−1,393	−1,758	−1,604	−1,467	−1,428	−1,934	−1,230	−1,030
Depreciation and amortisation	9	7	6	13	16	24	16	17
Stock-based pay	0	0	106	0	0	157	329	0
Capital spending	4	0	18	7	0	6	—	0
Free cash flow	−1,397	−1,758	−1,622	−1,475	−1,428	−1,940	—	−1,030
Free cash flow after stock pay	−1,397	−1,758	−1,727	−1,475	−1,428	−2,097	—	−1,030
Shares issued	—	—	—	—	0	2,728	2,990	2,071

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: LUCD vs NRXS MCTA vs NRXS BIAF vs NRXS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuraxis, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuraxis, Inc.